Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Objective: Hepatitis D virus (HDV) is a defective virus that completes its life cycle only with hepatitis B virus (HBV). The HBV with HDV super-infection has been considered as one of the most severe forms of the chronic viral hepatitis. However, there is a scarcity of data on the global burden of HDV infection. Design: We searched PubMed, Embase, Cochrane Library and China Knowledge Resource Integrated databases from 1 January 1977 to 31 December 2016. We included studies with a minimum sample size of 50 patients. Our study analysed data from a total of 40 million individuals to estimate the prevalence of HDV by using Der-Simonian Laird random-effects model. The data were further categorised according to risk factors. Results: From a total of 2717 initially identified studies, only 182 articles from 61 countries and regions met the final inclusion criteria. The overall prevalence of HDV was 0.98% (95% CI 0.61 to 1.42). In HBsAg-positive population, HDV pooled prevalence was 14.57% (95% CI 12.93 to 16.27): Seroprevalence was 10.58% (95% CI 9.14 to 12.11) in mixed population without risk factors of intravenous drug use (IVDU) and high-risk sexual behaviour (HRSB). It was 37.57% (95% CI 29.30 to 46.20) in the IVDU population and 17.01% (95% CI 10.69 to 24.34) in HRSB population. Conclusion: We found that approximately 10.58% HBsAg carriers (without IVDU and HRSB) were coinfected with HDV, which is twofold of what has been estimated before. We also noted a substantially higher HDV prevalence in the IVDU and HRSB population. Our study highlights the need for increased focus on the routine HDV screening and rigorous implementation of HBV vaccine programme.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
Vos, T., Abajobir, A. A., Abate, K. H., Abbafati, C., Abbas, K. M., Abd-Allah, F., Abdulkader, R. S., Abdulle, A. M., Abebo, T. A., Abera, S. F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32154-2 · Cited by 13,220
Self-citationSchweitzer, A., Horn, J., Mikolajczyk, R. T., Krause, G., & Ott, J. J. (2015) · The Lancet · doi:10.1016/s0140-6736(15)61412-x · Cited by 2,742
Transformations Related to the Angular and the Square Root
Freeman, M. F., & Tukey, J. W. (1950) · The Annals of Mathematical Statistics · doi:10.1214/aoms/1177729756 · Cited by 2,628
Nelson, P. K., Mathers, B. M., Cowie, B., Hagan, H., Des Jarlais, D., Horyniak, D., & Degenhardt, L. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61097-0 · Cited by 1,267
Platt, L., Easterbrook, P., Gower, E., McDonald, B., Sabin, K., McGowan, C., Yanny, I., Razavi, H., & Vickerman, P. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00485-5 · Cited by 731
Hughes, S. A., Wedemeyer, H., & Harrison, P. M. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61931-9 · Cited by 570
Treatment of Chronic Hepatitis D with Interferon Alfa-2a
Farci, P., Mandas, A., Coiana, A., Lai, M. E., Desmet, V. J., Eyken, P. V., Gibo, Y., Caruso, L., Scaccabarozzi, S., Criscuolo, D., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199401133300202 · Cited by 325
Late HDV RNA Relapse After Peginterferon Alpha-Based Therapy of Chronic Hepatitis Delta
Heidrich, B., Yurdaydın, C., Kabaçam, G., Ratsch, B. A., Zachou, K., Bremer, B., Dalekos, G. N., Erhardt, A., Tabak, F., Yalcin, K., et al. (2014) · Hepatology · doi:10.1002/hep.27102 · Cited by 301
The hepatitis delta virus: Replication and pathogenesis
Sureau, C., & Negro, F. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.02.013 · Cited by 276
Koh, C., Canini, L., Dahari, H., Zhao, X., Uprichard, S. L., Haynes-Williams, V., Winters, M. A., Subramanya, G., Cooper, S. L., Pinto, P., et al. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00074-2 · Cited by 269
Farci, P. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00331-3 · Cited by 245
The increasing prevalence of hepatitis delta virus (HDV) infection in South London
Cross, T. J. S., Rizzi, P., Horner, M., Jolly, A., Hussain, M. J., Smith, H. M., Vergani, D., & Harrison, P. M. (2008) · Journal of Medical Virology · doi:10.1002/jmv.21078 · Cited by 184
Stockdale, A. J., Chaponda, M., Beloukas, A. I., Phillips, R. O., Matthews, P. C., Papadimitropoulos, A., King, S., Bonnett, L. J., & Geretti, A. M. (2017) · The Lancet Global Health · doi:10.1016/s2214-109x(17)30298-x · Cited by 169
Hepatitis delta virus: insights into a peculiar pathogen and novel treatment options
Lempp, F. A., Ni, Y., & Urban, S. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.126 · Cited by 163
Infection and Cancer: The Case of Hepatitis B
Chan, S. L., Wong, V. W. S., Qin, S., & Chan, H. L. Y. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.5724 · Cited by 162
Hepatitis delta-associated mortality in HIV/HBV-coinfected patients
Béguelin, C., Moradpour, D., Sahli, R., Suter‐Riniker, F., Lüthi, A. U., Cavassini, M. L., Günthard, H. F., Battegay, M., Bernasconi, E., Schmid, P., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.10.007 · Cited by 145
Battlefield against hepatitis B infection and HCC in Africa
Lemoine, M., & Thursz, M. R. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.10.013 · Cited by 131
Chen, X., Oidovsambuu, O., Liu, P., Grosely, R., Elazar, M., Winn, V. D., Fram, B. J., Boa, Z., Dai, H., Dashtseren, B., et al. (2016) · Hepatology · doi:10.1002/hep.28957 · Cited by 111
Global Routine Vaccination Coverage, 2015
Casey, R. M., Dumolard, L., Danovaro-Holliday, M. C., Gacic-Dobo, M., Diallo, M. S., Hampton, L. M., & Wallace, A. S. (2016) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6545a5 · Cited by 108
Lin, H.-H., Lee, S. S., Yu, M., Chang, T., Su, C., Hu, B.-S., Chen, Y., Huang, C., Lai, C., Lin, J., et al. (2015) · Hepatology · doi:10.1002/hep.27742 · Cited by 84
Hepatitis D infection: from initial discovery to current investigational therapies
Da, B. L., Heller, T., & Koh, C. (2019) · Gastroenterology report · doi:10.1093/gastro/goz023 · Cited by 58
Chronic hepatitis D at a standstill: where do we go from here?
Ciancio, A., & Rizzetto, M. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.164 · Cited by 49
Cited by
Global burden of liver disease: 2023 update
Devarbhavi, H., Asrani, S. K., Arab, J. P., Nartey, Y. A., Pose, E., & Kamath, P. S. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.017 · Cited by 2,267
Miao, Z., Zhang, S., Ou, X., Li, S., Ma, Z., Wang, W., Peppelenbosch, M. P., Liu, J., & Pan, Q. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiz633 · Cited by 356
Liver diseases: epidemiology, causes, trends and predictions
Gan, C., Yuan, Y., Shen, H., Gao, J., Kong, X., Che, Z., Guo, Y., Wang, H., Dong, E., & Xiao, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02072-z · Cited by 310
EASL Clinical Practice Guidelines on hepatitis delta virus
Brunetto, M. R., Ricco, G., Negro, F., Wedemeyer, H., Yurdaydin, C., Asselah, T., Papatheodoridis, G., Gheorghe, L., Agarwal, K., Farci, P., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.05.001 · Cited by 294
Metadata
- Authors
- Chen, H.-Y., Shen, D.-T., Ji, D.-Z., Han, P.-C., Zhang, W.-M., Ma, J.-F., Chen, W.-S., Goyal, H., Pan, S., & Xu, H.-G.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2018-09-18
- Volume
- 68
- Issue
- 3
- Pages
- 512-521
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2891216657
- Cited by
- 397
- References
- 25
- FWCI
- 6.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.